Demystified: Monoclonal antibodies

Journal of Clinical Pathology - Molecular Pathology

Volumn 53, Issue 3, 2000, Pages 111-117

  Nelson, P N ^a   Reynolds, G M ^a   Waldron, E E ^a   Ward, E ^a   Giannopoulos, K ^a   Murray, P G ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

'magic bullets'; Hybridomas; Monoclonal antibodies

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN DETECTION; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY; MOLECULAR INTERACTION; MOLECULAR MODEL; PATHOLOGY; PRIORITY JOURNAL; REVIEW; BIOSYNTHESIS; HYBRIDOMA; IMMUNOLOGY; NEOPLASM;

ANTIBODIES, MONOCLONAL; HUMANS; HYBRIDOMAS; NEOPLASMS;

EID: 0034085659     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.53.3.111     Document Type: Review

References (51)

1. 1 Nelson PN, Westwood OM, Jefferis R, et al. Characterisation of anti-IgG monoclonal antibody A57H by epitope mapping. Biochem Soc Trans 1997;25:373.
2. 2 Nelson PN, Fletcher SM, De Lange GG, et al. Evaluation of monoclonal antibodies with putative specificity for human IgG allotypes. Vox Sang 1990;59:190-7.
3. 3 Nelson PN, Fletcher SM, MacDonald D, et al. Assay restriction profiles of three monoclonal antibodies recognizing the G3m(u) allotype: development of an allotype specific assay. J Immunol Methods 1991;138:57-64.
4. 4 Blottiere HM, Daculsi G, Anegon I, et al. Utilization of activated U937 monocytic cells as a model to evaluate biocompatibility and biodegradation of synthetic calcium phosphate. Biomaterials 1995;16:497-503.
5. 5 Hudson PJ. Recombinant antibody constructs in cancer therapy. Curr Opin Immunol 1999;11:548-57.
6. 6 Cragg MS, French RR, Glennie MJ. Signaling antibodies in cancer therapy. Curr Opin Immunol 1999;11:539-40.
7. 7 Jefferis R, Reimer CB, Skvaril F, et al. Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of an IUIS/WHO collaborative study. Immunol Lett 1985;10:223-8.
8. 8 Bull H, Choy M, Manyonda I, et al. Reactivity and assay restriction profiles of monoclonal and polyclonal antibodies to acid phosphatases: a preliminary study. Immunol Lett 2000 [In press.]
9. 9 Tzioufas AG, Yiannaki E, Sakarellos-Daitsiotis M, et al. Fine specificity of autoantibodies to La/SSB: epitope mapping and characterization. Clin Exp Immunol 1997;108: 191-8.
10. 10 Cole MS, Stellrecht KE, Shi JD, et al. HuM291, a humanised anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 1999;68:563-71.
11. 11 Cole MS, Anasetti C, Tso JY. Human IgG2 variants of chimeric anti-CD3 are non-mitogenic to T cells. J Immunol 1997;159:3631-21.
12. 12 Kreitman RJ. Immunotoxins in cancer therapy. Curr Opin Immunol 1999;11:570-8.
13. 13 Ordonez NG. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999;30:313-23.
14. 14 Ordonez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. Am J Clin Pathol 1999;112:75-89.
15. 15 Pendas S, Dauway E, Cox CE, et al. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients. Am Surg 1999;65:500-5.
16. 16 Czerniecki BJ, Scheff AM, Callans LS, et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 1999;85:1098-103.
17. 17 Brink AA, Oudejans JJ, van den Brule AJ, et al. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance? Mod Pathol 1998;11:376-83.
18. 18 Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244-51.
19. 19 Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 1995;72:1324-9.
20. 20 Matsushima H, Kitamura T, Goto T, et al. Combined analysis with Bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol 1997;158:2278-83.
21. 21 Fredersdorf S, Burns J, Milne AM, et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Prof Natl Acad Sci U S A 1997;94:6380-5.
22. 22 Porter PL, Malone KE, Heagerry PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
23. 23 Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997;57:1259-63.
24. 24 Thomas GV, Szigeti K, Murphy M, et al. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 1998;153:681-7.
25. 25 Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159:941-5.
26. 26 Erlanson M, Portin C, Linderholm B, et al. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas - prognostic implications. Blood 1998;92:770-7.
27. 27 Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mol Pathol 1998;11:155-68.
28. 28 Goussard J. Paraffin section immunocytochemistry and cytosol-based ligand-binding assays for ER and PR detection in breast cancer: the time has come for more objectivity. Cancer Lett 1998;132:61-6.
29. 29 Barclay AN, Brown MH, Law SKA, et al. The leukocyte antigen facts book, San Diego: Academic Press.
30. 30 Stein H, Hummel M. Cellular origin and clonality of classic Hodgkin's lymphoma: immunophenotypic and molecular studies. Semin Hematol 1999;36:233-41.
31. 31 Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998;10:457-70.
32. 32 Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-c2b8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-9.
33. 33 Maloney D, Grillo-López A, White C, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-92.
34. 34 McLaughlin P, Cabanillas F, Grillo-Lopez AJ, et al. IDEC-C2B8 anti-CD20 antibody: final report on a phase III pivotal trial in patients with relapsed low-grade or follicular lymphoma [abstract]. Blood 1996;88:90a.
35. 35 Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92;1927-32.
36. 36 Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-8.
37. 37 Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines [abstract]. Blood 1996;88:637a.
38. 38 De Potter CR. The neu oncogene: more than just a prognostic indicator? Hum Pathol 1994;25:1264-8.
39. 39 Quenel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995;35:283-91.
40. 40 O'Malley FP, Saad Z, Kerkvliet N, et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB2 in lymph node negative breast cancer. Hum Pathol 1996;27:955-63.
41. 41 Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-7.
42. 42 Molina R, Ciocca DR, Tandon AK, et al. Expression of HER-2/neu oncoprotein in breast cancer: a comparison of immunohistochemical and western blot techniques. Anticancer Res 1992;12:1965-91.
43. 43 Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118-21.
44. 44 Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702-8.
45. 45 Newby JC, Johnston SR, Smith IE, et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997;3:1643-51.
46. 46 Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999;9:125-38.
47. 47 Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/ neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
48. 48 Slamon D, Leyland-Jones B, Shak S. Addition of Herceptin (humanized anti-HER-2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled phase III trial [abstract]. Proc ASCO 1998;17:98a.
49. 49 Liu X, Pogo BG. Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1996;6:9-16.
50. 50 Brossart P, Stuhler G, Flad T, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998;58:732-6.
51. 51 Disis ML, Grabstein KH, Cheaver MA. HER-2/neu peptide vaccines elicit T cell immunity to the HER-2/neu protein in patients with breast and ovarian cancer [abstract]. Proc ASCO 1998;17:97a.